Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)

China · Delayed Price · Currency is CNY

7.96

-0.07 (-0.87%)

Nov 6, 2026, 3:00 PM CST

Market Cap	15.57B -11.8%
Revenue (ttm)	3.21B +16.2%
Net Income	544.64M -55.5%
EPS	0.28 -56.7%
Shares Out	1.96B
PE Ratio	28.62
Forward PE	30.62
Dividend	0.30 (3.77%)
Ex-Dividend Date	Jun 5, 2026

Volume	11,242,018
Open	7.91
Previous Close	8.03
Day's Range	7.90 - 8.03
52-Week Range	7.16 - 10.67
Beta	0.11
Analysts	Buy
Price Target	9.85 (+23.77%)
Earnings Date	Oct 29, 2026

About SHA:600867

Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenami... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1985

Employees 3,354

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600867

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 600867 stock is "Buy." The 12-month stock price target is ¥9.85, which is an increase of 23.77% from the latest price.

Price Target

¥9.85

(23.77% upside)

Analyst Consensus: Buy

Stock Forecasts